How Edwards Lifesciences Makes its Money: Revenue Breakdown
A breakdown of Edwards Lifesciences (EW) financials. See how Edwards Lifesciences makes money from Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral & Tricuspid Therapies (TMTT), Surgical Structural Heart using their 2024 annual report.
How Does Edwards Lifesciences Make its Money?
Edwards Lifesciences is the global leader in transcatheter heart valves and hemodynamic monitoring. The company pioneered the field of transcatheter aortic valve replacement (TAVR) with its SAPIEN platform, which allows doctors to replace diseased heart valves without open-heart surgery. Edwards commands over 60% of the global TAVR market and has been expanding into transcatheter mitral and tricuspid valve repair and replacement — a massive untapped opportunity. The company recently sold its Critical Care business to focus entirely on structural heart therapies.
Edwards’ dominance in TAVR creates a powerful competitive moat. The company has invested over 20 years in developing the clinical evidence, physician training infrastructure, and procedural expertise required for transcatheter heart valve therapy. Over 1 million TAVR procedures have been performed globally, and Edwards’ SAPIEN valve platform has the deepest clinical evidence base. Physicians who have been trained on SAPIEN and performed hundreds of procedures are reluctant to switch to competitors (Medtronic’s CoreValve, Abbott’s Portico), and hospitals have invested in the procedural workflows around Edwards’ products. This creates high switching costs and physician loyalty that protects market share.
Edwards Lifesciences (EW) Business Model
Edwards Lifesciences Competitors
Edwards Lifesciences’s key competitors and comparable public companies in the medical devices sector include Medtronic, Boston Scientific, Abbott Laboratories, and Intuitive Surgical. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Edwards Lifesciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Transcatheter Aortic Valve Replacement (TAVR) | $4,200 | $3,900 | +7.7% |
| Transcatheter Mitral & Tricuspid Therapies (TMTT) | $300 | $200 | +50.0% |
| Surgical Structural Heart | $1,100 | $1,000 | +10.0% |
| Total Revenue | $5,600 | $5,800 | -3.4% |
Transcatheter Aortic Valve Replacement (TAVR) — 75% of Revenue
Edwards’ flagship business and the product that transformed the treatment of aortic stenosis (narrowing of the heart’s aortic valve). TAVR allows cardiologists to implant a replacement heart valve through a catheter inserted via the femoral artery — avoiding the need for open-heart surgery, which requires cracking the chest and stopping the heart. The SAPIEN 3 Ultra and newer SAPIEN X4 platforms are the market-leading products, commanding over 60% global market share. Revenue grew 7.7% in 2024, driven by continued procedure volume growth and new patient populations.
The long-term growth thesis for TAVR is treatment expansion. Initially approved only for inoperable patients (those too sick for surgery), TAVR has been progressively expanded to high-risk, intermediate-risk, and now low-risk patients. The next frontier is treating moderate aortic stenosis — patients with significant valve narrowing who currently receive no treatment (the guidelines call for “watchful waiting”). Edwards’ EARLY TAVR clinical trial is studying whether treating moderate AS patients before they deteriorate improves outcomes. If successful, this could double or triple the addressable patient population from the current ~300,000 annual procedures to potentially 800,000+ globally. International markets, particularly Japan, China, and emerging economies, remain significantly underpenetrated.
Transcatheter Mitral & Tricuspid Therapies (TMTT) — 5% of Revenue
Edwards’ emerging business developing transcatheter therapies for mitral and tricuspid valve disease — conditions that affect millions of patients globally but currently have limited treatment options (mitral valve disease alone affects 4+ million people in the US). Revenue surged 50.0% in 2024 from a small base, driven by early adoption of the PASCAL repair system and the EVOQUE tricuspid replacement valve (the first transcatheter tricuspid replacement approved by the FDA).
TMTT represents the next chapter of Edwards’ growth story. Mitral and tricuspid valve diseases are more complex than aortic stenosis — the anatomy is more varied and the procedures are more technically demanding. Edwards is investing heavily in R&D and clinical trials to develop effective transcatheter solutions. The PASCAL system competes with Abbott’s MitraClip in mitral repair, while EVOQUE created a new market for tricuspid replacement. Success in TMTT could eventually generate revenue comparable to the TAVR business, but the development timeline is measured in years, not quarters.
Surgical Structural Heart — 20% of Revenue
Traditional surgical heart valves and repair products used in open-heart surgery. Revenue grew 10.0% in 2024, driven by premium products like the INSPIRIS RESILIA tissue valve (which uses anti-calcification technology to extend valve durability) and the HARPOON beating-heart mitral repair system. While the overall market for surgical heart valves is mature (TAVR is steadily replacing surgical procedures in many patient populations), Edwards continues to innovate in this space.
The Surgical segment provides stable revenue and high margins while TAVR captures the growth. There’s a natural pipeline from surgical to transcatheter — the clinical expertise and physician relationships built over decades in surgical heart valves is the same network that adopts Edwards’ transcatheter technologies.
Edwards Lifesciences (EW) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $5,600 | $5,800 |
| Cost of Revenue | $1,300 | $1,400 |
| Gross Profit | $4,300 | $4,400 |
| Operating Expenses | $2,400 | $2,500 |
| Operating Income | $1,900 | $1,900 |
| Net Income | $1,400 | $1,500 |
All values in millions USD unless otherwise stated.
Financial data sourced from Edwards Lifesciences SEC Filings.
Edwards Lifesciences (EW) Key Financial Metrics
- Gross Margin: 76.8%
- Operating Margin: 33.9%
- Revenue Growth: -3.4%
Is Edwards Lifesciences Profitable?
Yes, Edwards Lifesciences is highly profitable with medical device margins that reflect its premium market position. The 76.8% gross margin is exceptional — heart valves are precision-engineered devices with high selling prices ($30,000+ per valve) and relatively modest manufacturing costs once the R&D investment is recovered. The 33.9% operating margin demonstrates that Edwards converts gross profit efficiently into operating income despite significant R&D spending (~17% of revenue) required to maintain its technology lead. The -3.4% total revenue decline is misleading — it reflects the divestiture of the Critical Care business, not organic weakness. Excluding the divestiture, the core structural heart business grew in the high single digits. Net income of $1.4 billion was stable despite the top-line decline. The TMTT segment is currently unprofitable (absorbing significant R&D and commercial launch costs), which dilutes the consolidated operating margin. As TMTT scales and moves toward profitability, the overall margin profile should improve.
Edwards Lifesciences (EW): What to Watch
- EARLY TAVR trial results — The clinical trial studying TAVR in moderate aortic stenosis is the single most important catalyst for Edwards. Positive results could expand the addressable market by 2-3x and reignite double-digit TAVR revenue growth.
- TMTT commercialization — The pace of PASCAL and EVOQUE adoption, new indication approvals, and the path to TMTT profitability will determine whether Edwards can replicate its TAVR success in mitral and tricuspid therapies.
- Competitive dynamics in TAVR — Medtronic (Evolut PRO+), Abbott (Navitor), and Boston Scientific (ACURATE) compete in TAVR. Edwards’ market share stability versus competitive gains is a key health indicator for the franchise.
- International TAVR penetration — Japan, China, and other markets have TAVR penetration rates far below the US and Europe. Regulatory approvals, physician training, and reimbursement expansion in these markets represent a multi-year growth opportunity.
- Post-Critical Care focus — Having divested Critical Care, Edwards is now a pure-play structural heart company. The ability to deploy the capital from the sale ($3.4 billion) into share buybacks, M&A, or R&D acceleration will impact shareholder returns.
Edwards Lifesciences (EW) Financial Summary
Edwards Lifesciences dominates the transcatheter heart valve market with 60%+ global TAVR market share, built on 20+ years of clinical evidence and physician training. Revenue declined 3.4% to $5.6 billion in 2024 due to the Critical Care divestiture, but the core business grew solidly — TAVR (75% of revenue) grew 7.7% and TMTT (5%) surged 50% from its emerging base. The 76.8% gross margin and 33.9% operating margin reflect the premium economics of life-saving medical devices. The pivotal catalyst is the EARLY TAVR trial — if treating moderate aortic stenosis proves beneficial, the addressable patient population could more than double, and beyond that, the TMTT opportunity (mitral and tricuspid therapies) represents a potential second growth engine that could eventually rival TAVR in scale.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.